Hepatocellular carcinoma (HCC) is a high-fatality cancer with complex pathogenesis, often arising in the setting of various chronic liver diseases when it is too late to offer any curative therapy. This PhD thesis is divided into two parts, the first of which was completed at McGill University under the supervision of Dr. Nahum Sonenberg, and evaluated inhibition of translation downstream of mTOR. This work was performed in the context of much interest in inhibiting the mTOR pathway in HCC, given its identification as a dominant pathway in this cancer. In the first part of this thesis, I evaluated how metformin inhibits HCC growth, by decreasing translation of anti-apoptotic proteins such as Mcl-1 downstream of mTOR. In the second part of t...
International audienceIntegrative genomics helped characterize molecular heterogeneity in hepatocell...
Liver cancer has the second highest worldwide cancer mortality rate and has limited therapeutic opti...
Background & Aims: The advent of targeted therapies in hepatocellular carcinoma (HCC) has underscore...
Hepatocellular carcinoma (HCC) is a high-fatality cancer with complex pathogenesis, often arising in...
International audienceHepatocellular carcinoma (HCC) represents one of the most frequently diagnosed...
Objective: Various treatments have greatly reduced the mortality of hepatocellular carcinoma (HCC). ...
DoctorLiver cancer is the third most common cause of cancer-related mortality worldwide. Liver tumor...
Hepatocellular carcinoma (HCC) is a devastating disease worldwide. Though many efforts have been mad...
Copyright © 2014 Liwei Zhuang et al. This is an open access article distributed under the Creative C...
Suzana Bracic Tomazic,1,2,* Christoph Schatz,3,* Johannes Haybaeck3,4 1Department of Patholo...
Objective Hepatocellular carcinoma (HCC) is a common cancer with a high mortality rate; the molecula...
Hepatocellular carcinoma (HCC) is a leading cause of global cancer mortality. However, little is kno...
Hepatocellular carcinoma (HCC) is one of the most frequent forms of liver cancer, and effective trea...
Hepatocellular carcinomas (HCCs) have different etiology and heterogenic genomic alterations lead to...
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and has poor outcomes. Howe...
International audienceIntegrative genomics helped characterize molecular heterogeneity in hepatocell...
Liver cancer has the second highest worldwide cancer mortality rate and has limited therapeutic opti...
Background & Aims: The advent of targeted therapies in hepatocellular carcinoma (HCC) has underscore...
Hepatocellular carcinoma (HCC) is a high-fatality cancer with complex pathogenesis, often arising in...
International audienceHepatocellular carcinoma (HCC) represents one of the most frequently diagnosed...
Objective: Various treatments have greatly reduced the mortality of hepatocellular carcinoma (HCC). ...
DoctorLiver cancer is the third most common cause of cancer-related mortality worldwide. Liver tumor...
Hepatocellular carcinoma (HCC) is a devastating disease worldwide. Though many efforts have been mad...
Copyright © 2014 Liwei Zhuang et al. This is an open access article distributed under the Creative C...
Suzana Bracic Tomazic,1,2,* Christoph Schatz,3,* Johannes Haybaeck3,4 1Department of Patholo...
Objective Hepatocellular carcinoma (HCC) is a common cancer with a high mortality rate; the molecula...
Hepatocellular carcinoma (HCC) is a leading cause of global cancer mortality. However, little is kno...
Hepatocellular carcinoma (HCC) is one of the most frequent forms of liver cancer, and effective trea...
Hepatocellular carcinomas (HCCs) have different etiology and heterogenic genomic alterations lead to...
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and has poor outcomes. Howe...
International audienceIntegrative genomics helped characterize molecular heterogeneity in hepatocell...
Liver cancer has the second highest worldwide cancer mortality rate and has limited therapeutic opti...
Background & Aims: The advent of targeted therapies in hepatocellular carcinoma (HCC) has underscore...